Skip to content

    Tirzepatide and semaglutide went head-to-head: what did the study compare?

    Tirzepatide and semaglutide went head-to-head: what did the study compare?

    When people compare weight-management medicines, they often start with two numbers from two different studies. That can be misleading: the participants, length of follow-up, and support offered may not have been the same.

    One study, called SURMOUNT-5, put tirzepatide and semaglutide in the same trial. The results give us a clearer comparison for the people and treatments studied. They don't tell every individual which medicine is right for them.

    Who took part?

    The trial randomly assigned 751 adults to one of the two medicines. Participants had a body mass index of at least 30, or at least 27 along with a specified weight-related health condition. They did not have diabetes and had reported an unsuccessful dietary effort to lose weight.

    That last detail about diabetes matters when interpreting the results. The study doesn't directly answer how the same comparison would turn out for someone with type 2 diabetes. Nor does it cover every age, health history, or previous treatment experience.

    Participants received their assigned medicine as a weekly injection for 72 weeks. They also received counseling about nutrition and physical activity. The comparison was between two medication-based plans within that study, not between medicine and no support at all.

    What exactly was compared?

    Participants were assigned to tirzepatide or semaglutide, with doses increased according to the study protocol. The comparison focused on the highest doses specified in the study that participants could tolerate: tirzepatide at 10 or 15 milligrams and injectable semaglutide at 1.7 or 2.4 milligrams.

    Those numbers describe the research groups, not a recommendation for a reader to select a dose. The study also didn't compare every form or strength of either medicine. A result for the injections and doses used in this trial shouldn't be assumed to apply unchanged to a different formulation.

    The trial was open-label, meaning participants and the study team knew which medicine had been assigned. Random assignment helps make the groups comparable at the start, but knowing the treatment is still a feature to keep in mind, particularly when considering experiences people report.

    What did researchers find about weight?

    The main result was the estimated average percentage change in body weight from the beginning of the study to week 72. The tirzepatide group had an estimated average decrease of 20.2%; the semaglutide group had an estimated average decrease of 13.7%. That is a difference of 6.5 percentage points between the group estimates.

    An average isn't a promise. It includes people whose experiences differed from one another, and it doesn't predict what a particular person will lose. The analysis also had a defined way of handling treatment changes and missing information; the published numbers shouldn't be read as a guarantee for someone who takes a medicine for the same length of time.

    The researchers also measured waist circumference and looked at how many participants reached several weight-change thresholds. Tirzepatide had a larger average waist reduction in this comparison. Those are useful additional results, but they don't describe every outcome that might matter to a patient.

    What about side effects?

    Digestive problems were the most commonly reported adverse events in both groups. These included nausea, constipation, diarrhea, and vomiting. Many were described as mild or moderate and occurred particularly while doses were being increased. Some participants stopped the assigned treatment because of adverse events.

    Those group observations don't mean an individual will have the same experience, or that a symptom should be ignored because it was common in a study. If a medicine makes it hard to eat or drink, or a symptom is severe or persistent, contact your care team. If you cannot keep fluids down, seek urgent medical care. Ask what needs prompt attention before you begin treatment, not only after a problem arises.

    What the study doesn't settle

    The trial was designed to compare weight change and other outcomes over 72 weeks in a defined group. It wasn't a personal ranking of the medicines for every health goal. A treatment discussion may also involve your medical history, other medicines, tolerability, cost, access, and what you can reasonably maintain.

    It also matters who funded a study. This trial was funded by the company that makes tirzepatide. That doesn't by itself invalidate the findings, but it is useful context when looking at the design, results, and other available evidence.

    If you've already done well on one treatment, don't assume a group average is a reason to change it. Likewise, if a medicine isn't working well for you or is difficult to tolerate, the study is one piece of information to discuss—not a substitute for a plan with your clinician.

    Making the result useful

    At your next visit, you could ask: “How similar am I to the people in this study?” “Which outcomes matter most for my health?” and “What would we consider if side effects or cost become a problem?”

    SURMOUNT-5 offers a direct comparison at the doses and time point it studied. The most useful next step is to put that comparison beside your own priorities and health history, rather than treating either average as your expected result.